Precigen


Biopharmaceutical company developing gene and cell therapies across immuno-oncology, autoimmune and infectious disease. Operates platforms for adenoviral vector immunotherapies and non-viral multigenic CAR-T, advances programs through preclinical and clinical development, and has a marketed adenoviral vector immunotherapy for recurrent respiratory papillomatosis.

Industries

Biotechnology
Life Science
Medical
Therapeutics
Biotech & Pharmaceuticals
Pharmaceutical and biotechnology
Biotechnology Research

Nr. of Employees

large (251-1000)

Precigen

Germantown, Maryland, United States


Patents

Chimeric receptor therapy

US-12760083-B2

View Details

Fusion constructs and methods of using thereof

US-12703747-B2

View Details

Electroporation apparatus and method

US-12570945-B2

View Details

CD33 specific chimeric antigen receptors

US-12559536-B2

View Details

Human papillomavirus vaccines and uses of the same

US-12404306-B2

View Details

ROR-1 specific chimeric antigen receptors and uses thereof

US-12275772-B2

View Details
View All Patents

Products

PAPZIMEOS (zopapogene imadenovec‑drba)

Non‑replicating adenoviral vector‑based immunotherapy indicated for treatment of adults with recurrent respiratory papillomatosis; provided as a frozen single‑dose suspension for subcutaneous injection with a specified dosing schedule.


Services

Policy and contact pathway for physicians requesting pre‑approval access to investigational therapies.

Expertise Areas

  • Gene and viral vector therapy development
  • Autologous CAR‑T engineering and rapid manufacturing
  • Non‑viral genome engineering and integration systems
  • Translational immunology and vaccine research
  • Show More (4)

Key Technologies

  • Adenoviral vector systems for in vivo immunotherapy
  • Non‑viral transposon/transposase delivery
  • Site‑specific recombinase integration
  • Electroporation systems for cell modification
  • Show More (6)

News & Updates

Publication reporting results from a pivotal Phase 1/2 clinical trial of an adenoviral vector therapy in recurrent respiratory papillomatosis.

Study linking tumor microenvironment state to response to HPV therapeutic vaccination in patients with respiratory papillomatosis.

U.S. regulatory approval and full prescribing information issued for an adenoviral vector‑based immunotherapy for adults with recurrent respiratory papillomatosis (initial U.S. approval: 2025).


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.